| Title
of the article |
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients |
| Authors |
D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. |
| Journal
|
Kidney Int 2003; 63(s85): 73-78. |
| Subject
Consultant |
C. Zoccali |
| Score
(1 to 3 stars) |
** |
| Cross
referencing |
Uremia |
| Comments |
In this phase III, open-label study, Lanthanum Carbonate (a poorly absorbed and efficient phosphate binder) almost stopped the evolution toward low bone turnover over one year in lanthanum treated patients (unlike CC-treated patients). No important side effects were noted. |
